EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2025
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2021.09.06
Coronavirus Pandemic: Chinese developer shares efficacy of inhaled vaccines
2021.06.23
CanSinoBIO Announces Approval for Its Group A and Group C Meningococcal Conjugate Vaccine in China
2021.05.21
CanSinoBIO Receives EU GMP Certificate
2021.02.25
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine in China
2021.02.24
NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO’s COVID-19 Vaccine ConvideciaTM
2020.11.06
CanSinoBIO’s COVID-19 Vaccine Launched Phase III Clinical Trial in Mexico and Vaccinated the First Group of Subjects
2020.08.13
CanSinoBIO’s Successful Listing on STAR Market Makes it the Initial Dual Listing Vaccine Company
2020.03.17
CanSinoBIO’s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China
2020.01.02
CanSinoBIO Appoints Pierre Armand Morgon as Senior Vice President of International Business Operation
2019.12.16
CanSinoBIO's NDA for Investigational Quadrivalent Meningocococcal Conjugate Vaccine Granted with Priority Review Designation
1345678